Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab in Severe COVID-19 Pneumonia
NCT04399980Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing Mavrilimumab with Placebo (2 arms). Primary endpoint: Subjects Alive and Off of Oxygen at Day 14. Started May 2020; status: completed.
02
Drugs
mavrilimumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04399980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399980.